Inpatient Medicare TKA Patients Have Distinct Characteristics and Worse Outcomes: Implications for the New CMS PROMs Policy
The Journal of Knee Surgery · 01.05.2026 · 39 (06) · 303-309
DOI: 10.1055/a-2741-1586 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Knee Surgery, erschienen am 01.05.2026. Verfasst von Khaled A Elmenawi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio, United States. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Knee, Medicare, Patient Reported Outcome Measures. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
The Centers for Medicare and Medicaid Services (CMS) recently mandated the collection of Patient-Reported Outcome-Based Performance Measures (PRO-PMs) for Medicare patients undergoing inpatient total knee arthroplasty (TKA). The policy's generalizability remains a concern. Therefore, we aimed to compare PROMs capture rates, patients' characteristics, and achieving the substantial clinical benefit (SCB) threshold between inpatient and outpatient Medicare TKA. A prospective cohort of Medicare patients aged ≥ 65 who underwent primary TKA between 2016 and 2022 at a single health system was analyzed (n = 7,926). Patients were categorized as inpatient (length of stay [LOS] > 24 hours, n = 2,812) or outpatient (LOS ≤ 24 hours, n = 5,114). Capture rates of CMS-mandated variables, baseline characteristics, and 1-year outcomes were compared. SCB was defined as a 20-point improvement in the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR) per CMS criteria. Baseline capture rates were similar between groups (approximately 82.8%), but 1-year KOOS-JR completion was lower for inpatients (53.3% vs. 62.4%). Inpatients had higher comorbidity burden (CCI ≥ 2: 40% vs. 33%, p < 0.001), worse KOOS-JR (median 44.9 vs. 47.5, p < 0.001), lower VR-12 MCS scores (50.2 vs. 54.1, p < 0.001), and more frequent nonoperative joint pain (75.1% vs. 68.6%, p < 0.001) and back pain (67.4% vs. 63.8%, p < 0.001). Outpatients trended toward better SCB achievement (OR: 0.89, 95% CI: 0.78–1.00, p = 0.054). Compared to outpatients, inpatient Medicare TKA patients had lower 1-year PROM capture rates, more comorbidities, and worse baseline PROMs, with a trend toward not meeting CMS SCB thresholds. These differences highlight limitations in using inpatient-only data to assess national TKA outcomes, especially as outpatient procedures grow. Nonetheless, future studies with higher power should validate these findings. The level of evidence is III (retrospective).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio, United States.
- Cleveland Clinic, Department of Biomedical Engineering, Cleveland, Ohio, United States.
ORCID-Profile: Nicolas S Piuzzi
Zitieren
APA
Elmenawi, K. A., Pasqualini, I., Jevnikar, B. E., Emara, A. K., Zhang, C., Piuzzi, N. S., & Cleveland Clinic Adult Reconstruction Research (CCARR) Group (2026). Inpatient Medicare TKA Patients Have Distinct Characteristics and Worse Outcomes: Implications for the New CMS PROMs Policy. The Journal of Knee Surgery, 39(06), 303-309. https://doi.org/10.1055/a-2741-1586
Vancouver
Elmenawi KA, Pasqualini I, Jevnikar BE, Emara AK, Zhang C, Piuzzi NS, et al. Inpatient Medicare TKA Patients Have Distinct Characteristics and Worse Outcomes: Implications for the New CMS PROMs Policy. The Journal of Knee Surgery. 2026;39(06):303-309. doi:10.1055/a-2741-1586
BibTeX
@article{Elmenawi2026,
author = {Elmenawi, Khaled A and Pasqualini, Ignacio and Jevnikar, Benjamin E and Emara, Ahmed K and Zhang, Chao and Piuzzi, Nicolas S and Cleveland Clinic Adult Reconstruction Research (CCARR) Group, Cleveland Clinic Adult Reconstruction Research (CCARR) Group},
title = {Inpatient Medicare TKA Patients Have Distinct Characteristics and Worse Outcomes: Implications for the New CMS PROMs Policy},
journal = {The Journal of Knee Surgery},
year = {2026},
volume = {39},
number = {06},
pages = {303--309},
doi = {10.1055/a-2741-1586}
}
EUVIMED